Targeting Purinergic Signaling for Perioperative Organ Protection

“Despite [our] remarkable progress, acute organ injury remains one of the leading causes for morbidity and mortality in surgical patients.”

ADVANCEMENTS

In the field of anesthesia have led to significant improvements in our monitoring capabilities, safer anesthetic drugs, and improved pain control. Despite this remarkable progress, acute organ injury remains one of the leading causes for morbidity and mortality in surgical patients. Patients who require a major surgical intervention—such as cardiothoracic, vascular, general surgery, or solid organ transplantation—may have had a “perfect” operation but are threatened during their perioperative course by the development of acute organ injury. For example, acute kidney injury, myocardial infarction, intestinal ischemia, and reperfusion injury or stroke are some of the threats that are among the leading causes of perioperative morbidity and mortality.1 A recent review article published in the New England Journal of Medicine discussed “Purinergic Signaling during Inflammation,”2 provides an update on how signaling events through extracellular receptors for the purines adenosine triphosphate (ATP) and adenosine can be targeted to alter inflammatory endpoints. As discussed in this review article, recent studies implicate purinergic signaling via ATP or adenosine receptors as important therapeutic targets to prevent or treat acute organ injury in perioperative patients.

In many instances, perioperative organ injury is caused by ischemia and comitant hypoxic-induced inflammation.3 Hypoxia and inflammation share an interdependent relationship, where inflammatory diseases such as intestinal inflammation or acute lung injury can cause inflamed areas to become severely hypoxic. This typically occurs because of increased metabolic demand of resident and inflammatory cells while metabolic supply is simultaneously decreased. However, diseases that are attributed primarily to hypoxia and ischemia will undergo secondary inflammatory changes that—in the context of ischemia and reperfusion injury—contribute significantly to organ injury (fig. 1).1

During hypoxic or inflammatory disease states, many cells release ATP from their intracellular toward the extracellular compartment. In the extracellular space, ATP can activate extracellular ATP receptors, which are classified as P2 receptors. They function as G-protein coupled receptors (P2Y receptors) or as ligand-gated ion channels (P2X receptors). Activation of P2 receptors has been shown to cause inflammatory activation and organ injury during ischemia or inflammation, and therapeutic strategies to dampen ATP receptor activation have been implicated in the treatment of inflammatory diseases.4–6

In the extracellular compartment, ATP is rapidly converted to adenosine. In contrast to the proinflamatory functions of ATP receptors, adenosine receptors have been shown to attenuate hypoxic inflammation,7 provide metabolic tissue adaptation to increase ischemia tolerance,8 and to promote injury resolution.9–11 Therefore, treatment approaches to enhance ATP conversion to adenosine represents an experimental therapeutic strategy to dampen acute organ injury. Conversion of ATP to adenosine is controlled by a two-step enzymatic system. The first step is the conversion of ATP to adenosine monophosphate by the ectonucleoside triphosphate diphosphohydrolase 1 (CD39). The subsequent second step in the extracellular generation of adenosine is catalyzed by the ecto-5′-nucleotidase CD73. Conditions of inflammatory hypoxia result in the induction of both enzymes (fig. 2). CD39 is transcriptionally induced by the Sp1 transcription factor,12 whereas CD73 is induced by hypoxia-inducible factor (HIF)—the key transcription factor for hypoxia adaptation.13,14 For example, HIF is known to regulate the transcriptional activity of the erythropoietin promoter. Conditions of hypoxia, ischemia, or anemia will lead to tissue hypoxia and subsequent stabilization of HIF. Binding of HIF to the erythropoietin promoter results in transcriptional induction of erythropoietin, leading to increases in erythropoiesis. Indeed, HIF activators have been implicated in treating inflammatory hypoxia via increasing tissue expression of CD73, thereby promoting the extracellular generation of adenosine.3

Once generated in the extracellular compartment, adenosine can activate four distinct adenosine receptors. These

Accepted for publication January 9, 2013. Dr. Eltzschig has no conflict of interest. The current research work was supported by National Institutes of Health (Bethesda, Maryland) Grants R01-HD921, R01-DK083885, R01-HD098240 and a grant by the Crohn’s and Colitis Foundation of America (New York, New York) to Dr. Eltzschig.

Copyright © 2013, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins. Anesthesiology 2013; 118:1001–4
are G-protein coupled receptors that differ in their sensitivity for adenosine, and the type of second message response they elicit. The Adora1 and Adora3 are known to inhibit adenylate cyclase, thereby leading to decreased intracellular cyclic adenosine monophosphate levels. In contrast, the Adora2a and Adora2b are known to activate adenylate cyclase and thereby increase cyclic adenosine monophosphate levels.15 In the context of organ protection, activation of Adora2a receptors expressed on inflammatory cells has been shown to provide tissue protection. Moreover, the Adora2b receptor is transcriptionally induced by HIF during conditions of ischemia or hypoxia,16 and has been shown to protect the tissues from the detrimental effects of hypoxia-driven inflammation (fig. 2).

In summary, current experimental evidence indicates that purinergic signaling events can be targeted to treat or prevent acute organ injury such as occurs during the perioperative period. These studies suggest the following pharmacologic approaches:

- Inhibition of signaling events through ATP receptors (e.g. P2Y or P2X receptors) by ATP receptor antagonists.
- Pharmacologic approaches that promote the extracellular conversion of ATP to adenosine, such as apyrase treatment (conversion of ATP to adenosine monophosphate) or nucleotidase treatment (conversion of adenosine monophosphate to adenosine). Several other pharmacologic compounds that are used in the treatment of inflammatory diseases (e.g. methotrexate or sulfasalazine) are known to exhibit their antiinflammatory properties by stimulating CD73-dependent adenosine production.
- Pharmacologic approaches to activate adenosine receptors, particularly the Adora2a or the Adora2b. For example, a highly selective Adora2b agonist has recently been characterized to function in murine or human tissues.8,17 This compound (BAY 60–6483) has been shown to have organ-protective functions in a wide range of disease models from the field of ischemia and reperfusion injury, for example intestinal ischemia13,18 or renal ischemia.10,11
- Pharmacologic approaches to indirectly increase extracellular adenosine signaling effects. This can be achieved
for example by adenosine transport inhibitors or by inhibitors of the metabolic breakdown of adenosine.

- Pharmacologic strategies to enhance transcriptional pathways that result in increased ATP to adenosine turnover and increased expression of adenosine receptors. This can be achieved for example by pharmacologic activators of the transcription factor HIF.

Most of these pharmacologic interventions have been identified and described in animal models. However, several pharmacologic agents that modulate purinergic signaling are being used in patients. For example, the antiinflammatory medications methotrexate or sulfasalazine are known to increase extracellular adenosine levels via activation of CD73. Similarly, the adenosine uptake inhibitor dipyridamole is used in patients during stress echocardiography. Finally, clinical studies have used HIF activators in patients without safety concerns. As such, we are hoping that several of these pharmacologic interventions can be used for the prevention of organ injury in surgical patients in the near future. However, efforts to go forward with translational studies, such as...

Fig. 2. Hypoxia control of extracellular adenosine generation and signaling. Histologic staining of intestinal sections for hypoxia shows that hypoxia is present within the apical surface of the intestinal mucosa (orange area in upper insert). This presence is most likely due to the fact that the intestinal lumen is anaerobic, which results in a steep oxygen gradient across the epithelial monolayer. In patients with intestinal inflammation such as that which occurs in the course of inflammatory bowel disease, a decrease in metabolic supply (e.g., due to thrombosed vessels) and profound increases in oxygen demand result in an imbalance in oxygen availability. This imbalance causes severe hypoxia of the inflamed mucosa, as indicated by histologic staining for tissue hypoxia (as shown in the lower insert, the orange staining that extends from the apical aspects of the mucosa into the crypts and submucosal tissues indicates severe tissue hypoxia). Release of adenosine triphosphate (ATP) or adenosine diphosphate (ADP) from inflammatory cells, platelets, or epithelial cells results in the activation of P2 receptors such as the P2X7 receptor, expressed on enteric neurons, thereby promoting tissue inflammation and injury. Hypoxia causes the activation of transcriptional programs that result in an Sp1-dependent induction of CD3917 and a hypoxia-inducible factor (HIF)–dependent induction of CD7325 and the ADORA2B (A2B) adenosine receptor. These transcriptional changes lead to an increased rate of turnover of the extracellular nucleotides ATP and ADP to adenosine monophosphate (AMP) (through CD39) and subsequently to adenosine (through CD73). Experimental studies indicate that adenosine receptor activation—particularly through Adora2a (A2A) and A2B—dampens hypoxia-induced inflammation and promotes tissue integrity. From Eltzschig HK, Sitkovsky MV, Robson SC Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
clinical randomized trials in perioperative patients will be required to make progress on this front.

The author acknowledges Shelley A. Eltzschig, B.S.B.A., artist, Mucosal Inflammation Program, University of Colorado School of Medicine, Aurora, Colorado, for artwork that inspired the figures included in this Editorial.

Holger K. Eltzschig, M.D., Ph.D., Mucosal Inflammation Program, Department of Anesthesiology, University of Colorado School of Medicine, Aurora, Colorado. holger.eltzschig@ucdenver.edu

References